NERV (Minerva Neurosciences) Cyclically Adjusted FCF per Share: $-5.52 (As of Mar. 2026)


NERV Minerva Neurosciences Inc NERV
32 GF Score
Price $4.83
! 1 Warning Sign
View Full Analysis

What is Minerva Neurosciences Cyclically Adjusted FCF per Share?

Minerva Neurosciences NERV -5.39% 32 Cyclically Adjusted FCF per Share is $-5.52 as of Mar. 2026. GuruFocus rates NERV with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Minerva Neurosciences's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.124. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-5.52 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 10.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Minerva Neurosciences was 10.00% per year. The lowest was 10.00% per year. And the median was 10.00% per year.

As of today (2026-07-06), Minerva Neurosciences's current stock price is $4.825. Minerva Neurosciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-5.52. Minerva Neurosciences's Cyclically Adjusted Price-to-FCF of today is .


Minerva Neurosciences  (NAS:NERV) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Minerva Neurosciences Cyclically Adjusted FCF per Share Related Terms


Minerva Neurosciences Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Minerva Neurosciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minerva Neurosciences Cyclically Adjusted FCF per Share Chart

Minerva Neurosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -7.73 -8.08 -6.44 -5.64

Minerva Neurosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.31 -6.08 -5.91 -5.64 -5.52

NERV vs TTRX, WHWK, IMUX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Minerva Neurosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minerva Neurosciences Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Minerva Neurosciences's Cyclically Adjusted Price-to-FCF falls into.


NERV
32GF Score
Minerva Neurosciences Inc NERV
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minerva Neurosciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Minerva Neurosciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.124/330.2130*330.2130
=-0.124

Current CPI (Mar. 2026) = 330.2130.

Minerva Neurosciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -1.663 241.018 -2.278
201609 -1.070 241.428 -1.463
201612 -2.048 241.432 -2.801
201703 -1.367 243.801 -1.852
201706 -1.491 244.955 -2.010
201709 4.871 246.819 6.517
201712 -1.841 246.524 -2.466
201803 -2.257 249.554 -2.986
201806 -2.317 251.989 -3.036
201809 -2.060 252.439 -2.695
201812 -2.016 251.233 -2.650
201903 -1.971 254.202 -2.560
201906 -2.077 256.143 -2.678
201909 -1.952 256.759 -2.510
201912 -2.906 256.974 -3.734
202003 -1.879 258.115 -2.404
202006 -1.507 257.797 -1.930
202009 -1.884 260.280 -2.390
202012 -1.341 260.474 -1.700
202103 -0.977 264.877 -1.218
202106 -1.110 271.696 -1.349
202109 -1.616 274.310 -1.945
202112 -0.905 278.802 -1.072
202203 -1.088 287.504 -1.250
202206 -0.972 296.311 -1.083
202209 -1.785 296.808 -1.986
202212 -0.770 296.797 -0.857
202303 -0.022 301.836 -0.024
202306 -0.703 305.109 -0.761
202309 -0.635 307.789 -0.681
202312 -0.790 306.746 -0.850
202403 -0.805 312.332 -0.851
202406 -0.520 314.175 -0.547
202409 -0.575 315.301 -0.602
202412 -0.683 315.605 -0.715
202503 -0.538 319.799 -0.556
202506 -0.270 322.561 -0.276
202509 -0.385 324.800 -0.391
202512 -0.402 324.054 -0.410
202603 -0.124 330.213 -0.124

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-5.52 mean?
Minerva Neurosciences (NERV) has a Cyclically Adjusted FCF per Share of $-5.52 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Minerva Neurosciences and its competitors.
Is Minerva Neurosciences' Cyclically Adjusted FCF per Share too high?
Minerva Neurosciences' current Cyclically Adjusted FCF per Share is $-5.52. Overall, Minerva Neurosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Minerva Neurosciences' Cyclically Adjusted FCF per Share compare to TTRX and WHWK?
Minerva Neurosciences' Cyclically Adjusted FCF per Share of $-5.52 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Minerva Neurosciences and its competitors. Minerva Neurosciences's current Cyclically Adjusted FCF per Share is $-5.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minerva Neurosciences stock overvalued right now?
Minerva Neurosciences (NERV) has a current Cyclically Adjusted FCF per Share of $-5.52. The current Cyclically Adjusted FCF per Share is $-5.52. Minerva Neurosciences' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Minerva Neurosciences (NERV), the current Cyclically Adjusted FCF per Share is $-5.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minerva Neurosciences Business Description

Other Exchanges 4MNA:Germany
Address 1500 District Avenue, Burlington, MA, USA, 01803
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
32GF Score

Get the complete analysis for NERV

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.83
Price